Loading
A phase 1/2 trial of Venetoclax in acute myeloid leukaemia, run by Delta-Fly Pharma, Inc., now recruiting.
DFP-10917 in Combination With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia is a phase 1/2 interventional study registered as NCT06382168 by Delta-Fly Pharma, Inc., with 39 participants planned, started 2024-06-12 and due to reach its primary completion in 2026-03-31. Interventions recorded: DFP-10917 and Venetoclax.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares BCL-2 inhibitors, Venetoclax, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/